Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Hansa Biopharma AB ( (SE:HNSA) ) is now available.
Hansa Biopharma AB held an Extraordinary General Meeting where it resolved to maintain the number of Board members at eight and elected Elisabeth Björk, Natalie Berner, and Michael Bologna as new members. The meeting also confirmed that the Board’s fees would remain unchanged, although Berner and Bologna declined remuneration. These changes in the Board composition could impact the company’s strategic direction and governance.
The most recent analyst rating on (SE:HNSA) stock is a Hold with a SEK33.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
More about Hansa Biopharma AB
Hansa Biopharma AB is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative treatments for rare immunological conditions. The company leverages its proprietary IgG-cleaving enzyme technology platform to address unmet medical needs in autoimmune diseases, gene therapy, and transplantation. Its portfolio includes imlifidase, an IgG antibody-cleaving enzyme therapy, and HNSA-5487, a next-generation IgG cleaving molecule.
Average Trading Volume: 403,002
Technical Sentiment Signal: Hold
Current Market Cap: SEK2.74B
See more insights into HNSA stock on TipRanks’ Stock Analysis page.